CRX.L Regulatory News (CRX)

11 Dec 2006 16:47

Cyprotex PLC11 December 2006 11 December 2006 Cyprotex Plc (the "Company" or "Cyprotex") Total Voting Rights and Share Capital In conformity with the Transparency Directive's transitional provision 6,Cyprotex is required to notify the market of the following: The issued share capital of Cyprotex consists of 138,573,016 ordinary shareswith a nominal value of 0.1 pence each, with voting rights. Cyprotex does nothold any ordinary shares in Treasury. Therefore, the total number of voting rights in Cyprotex is 138,573,016. The above figure of 138,573,016 shares may be used by shareholders as thedenominator for the calculations by which they will determine if they arerequired to notify their interest in, or a change to their interest in, Cyprotexunder the Financial Service Authority's Disclosure and Transparency Rules. Name of contact and telephone number for enquiries: Mark C. Warburton, Cyprotex Plc Company Secretary: +44 1625 505100 For further information:Cyprotex PLCRobert Morrisson Atwater, Chairman & Chief Executive OfficerTel: +44 (0) 1625 505 100ir@cyprotex.comhttp://www.cyprotex.com/ Nomura Code Securities LimitedCharles WalkerTel: +44 (0) 20 7776 1200cew@nomuracode.comhttp://www.nomuracode.com/ Media Enquires:WMC CommunicationsCharlie Geller/Alex GloverTel: +44 (0) 20 7930 9030charlie.geller@wmccommunications.com This information is provided by RNS The company news service from the London Stock Exchange